What is the composition of the Protein A-MCC-DM1 ADC?

The Protein A-MCC-DM1 ADC is composed of Protein A conjugated via an MCC linker to DM1. DM1 is a cytotoxic agent that targets certain cancers through immune recognition and is delivered into cancer cells via receptor-mediated endocytosis, leading to cell death by disrupting microtubule dynamics.

How does DM1 function in the Protein A-MCC-DM1 ADC?

DM1 functions by binding to tubulins within cancer cells, disrupting microtubule dynamics, and inducing cell death. This mechanism is activated after the ADC is internalized into target cells, making DM1 a potent cytotoxic agent for targeted cancer therapy.

What is the role of Protein A in the Protein A-MCC-DM1 ADC?

Protein A in this ADC binds to the Fc region of antibodies, facilitating the targeting of DM1 to specific cancer cells. This binding allows the ADC to leverage immune recognition of the Fc region, leading to receptor-mediated endocytosis of DM1 into cancer cells, where it exerts its cytotoxic effects.

What experimental considerations should be taken into account when using the Protein A-MCC-DM1 ADC?

When using this ADC, researchers should optimize the concentration and incubation times to ensure efficient binding and internalization. It is also important to include controls without primary antibodies to confirm the specificity of the cytotoxic effects and to ensure that any observed effects are due to the ADC's intended mechanism.

What support does Creative Biolabs offer for optimizing the use of Protein A-MCC-DM1 ADC in experiments?

Creative Biolabs offers comprehensive support for researchers using the Protein A-MCC-DM1 ADC, including technical consultation on experimental design, optimization of ADC concentration, and troubleshooting. They also provide guidance on selecting appropriate controls and ensuring the specificity of the ADC's cytotoxic effects.

Can the Protein A-MCC-DM1 ADC be customized for specific research needs?

Yes, Creative Biolabs offers customization services for the Protein A-MCC-DM1 ADC. Researchers can request modifications to the linker, conjugation process, or specific components to suit their experimental needs, allowing for tailored solutions that align with the research objectives.

Home
Products
Anti-Ab ADCs
IgG Fc
Protein A-MCC-DM1 ADC

Protein A-MCC-DM1 ADC (CAT#: ADC-AA-054)

This ADC product is comprised of a Protein A conjugated via a MCC linker to DM1. The DM1 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, DM1 binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death. This product displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening monoclonal antibodies as ADC candidates.

ADC Target
ADC Antibody
ADC Linker
ADC payload drug

Name
IgG Fc

Overview
The fragment crystallizable region (Fc region) is composed of the constant region of the two heavy chains that form the IgG molecule. The Fc region of IgG bears a highly conserved N-glycosylation site. Glycosylation of the Fc fragment is essential for Fc receptor-mediated activity. Fc binds to various cell receptors and complement proteins thus mediating different physiological effects of antibodies, such as opsonization, antibody dependent cellular cytotoxicity (ADCC), degranulation of mast cells, basophils, eosinophils and other processes.

Overview
Protein A

Name
MCC (Maleimidomethyl cyclohexane-1-carboxylate)

Description
Noncleavable linkers, is considered noncleavable-meaning linker cleavage, and payload release does not depend on the differential properties between the plasma and some cytoplasmic compartments. Instead, the release of the cytotoxic drug is postulated to occur after internalization of the ADC via antigen-mediated endocytosis and delivery to lysosomal compartment, where the antibody is degraded to the level of amino acids through intracellular proteolytic degradation.

Name
DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)

Description
Derived from Maytansinoid,a group of cytotoxins structurally similar to rifamycin, geldanamycin, and ansatrienin. The eponymous natural cytotoxic agent maytansine is a 19-member lactam (ansa
macrolide) structure originally isolated from the Ethiopian shrub Maytenus ovatus. Maytansinoids can bind to tubulin at or near the vinblastine-binding site, which interfere the formation of microtubules and depolymerize already formed microtubules, inducing mitotic arrest in the intoxicated cells.

For Research Use Only. NOT FOR CLINICAL USE.

Published Data

+ Submit Publications

Submit a review or a question

Scientific Resources

CAMouse™-Fully Human Antibody Generation Platform

Reviews

Literature

Protocol

Customer Reviews and FAQs

There are currently no Customer reviews or questions for ADC-AA-054. Click the button above to contact us or submit your feedback about this product.

Customer Reviews FAQ

Excellent

The Protein A-MCC-DM1 ADC from Creative Biolabs delivered exceptional results in our cancer research. The DM1 conjugation effectively disrupted microtubule dynamics, leading to significant cancer cell death with minimal off-target effects.

Excellent

Using the Protein A-MCC-DM1 ADC, we successfully pre-screened monoclonal antibodies for our ADC projects. The product's efficiency and economical value made it a valuable tool in our lab.

Excellent

This ADC product showed impressive specificity in targeting cancer cells. The Protein A-MCC-DM1 ADC provided potent cytotoxicity, significantly advancing our research on potential cancer therapies.

Excellent

Creative Biolabs' Protein A-MCC-DM1 ADC was highly effective in our experiments, providing reliable data for pre-screening ADC candidates. The product's targeted action and minimal toxicity were particularly noteworthy.

Excellent

We were very pleased with the Protein A-MCC-DM1 ADC. The product's ability to bind to tubulins and induce cell death with minimal side effects made it an ideal choice for our cancer research.

Q: 1: What is the composition of the Protein A-MCC-DM1 ADC?
A: The Protein A-MCC-DM1 ADC is composed of Protein A conjugated via an MCC linker to DM1. DM1 is a cytotoxic agent that targets certain cancers through immune recognition and is delivered into cancer cells via receptor-mediated endocytosis, leading to cell death by disrupting microtubule dynamics.
Q: 2: How does DM1 function in the Protein A-MCC-DM1 ADC?
A: DM1 functions by binding to tubulins within cancer cells, disrupting microtubule dynamics, and inducing cell death. This mechanism is activated after the ADC is internalized into target cells, making DM1 a potent cytotoxic agent for targeted cancer therapy.
Q: 3: What is the role of Protein A in the Protein A-MCC-DM1 ADC?
A: Protein A in this ADC binds to the Fc region of antibodies, facilitating the targeting of DM1 to specific cancer cells. This binding allows the ADC to leverage immune recognition of the Fc region, leading to receptor-mediated endocytosis of DM1 into cancer cells, where it exerts its cytotoxic effects.
Q: 4: What experimental considerations should be taken into account when using the Protein A-MCC-DM1 ADC?
A: When using this ADC, researchers should optimize the concentration and incubation times to ensure efficient binding and internalization. It is also important to include controls without primary antibodies to confirm the specificity of the cytotoxic effects and to ensure that any observed effects are due to the ADC's intended mechanism.
Q: 5: What support does Creative Biolabs offer for optimizing the use of Protein A-MCC-DM1 ADC in experiments?
A: Creative Biolabs offers comprehensive support for researchers using the Protein A-MCC-DM1 ADC, including technical consultation on experimental design, optimization of ADC concentration, and troubleshooting. They also provide guidance on selecting appropriate controls and ensuring the specificity of the ADC's cytotoxic effects.
Q: 6: Can the Protein A-MCC-DM1 ADC be customized for specific research needs?
A: Yes, Creative Biolabs offers customization services for the Protein A-MCC-DM1 ADC. Researchers can request modifications to the linker, conjugation process, or specific components to suit their experimental needs, allowing for tailored solutions that align with the research objectives.

Quick Links

ADC Toxins

Drug-linker Complexes

Customized ADCs

Anti-Ab ADCs

Other Products

Same Target Same Linker Same Payload

CAT#	Product Name	Linker	Payload
ADC-AA-021	anti-MIgG(Fc)-C-MMAE ADC	Cleavable linkers	MMAE (Monomethyl auristatin E)
ADC-AA-028	anti-MIgG(Fc)Fab-C-MMAF ADC	Cleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-026	anti-MIgG(Fc)-N-DM1 ADC	Noncleavable linkers	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-AA-027	anti-MIgG(Fc)Fab-N-MMAF ADC	Noncleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-048	Protein G-VC-MMAE ADC	VC (valine-citrulline)	MMAE (Monomethyl auristatin E)

CAT#	Product Name	Linker	Payload
ADC-W-511	Anti-ERBB2 (cFRP5)-MCC-DM1 ADC	MCC (Maleimidomethyl cyclohexane-1-carboxylate)	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-W-606	Anti-ERBB2-MCC-DM1 ADC	MCC (Maleimidomethyl cyclohexane-1-carboxylate)	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-W-487	Anti-CD70-MCC-DM1 ADC	MCC (Maleimidomethyl cyclohexane-1-carboxylate)	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-W-578	Anti-CD74-MCC-Dox ADC	MCC (Maleimidomethyl cyclohexane-1-carboxylate)	doxorubicin
ADC-W-534	Anti-ITGAE (clone M290)-MCC-DM1 ADC	Mcc (Maleimidomethyl cyclohexane-1-carboxylate)	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)

CAT#	Product Name	Linker	Payload
ADC-W-603	Anti-FOLH1 (clone J591)-SMCC-DM1 ADC	SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate)	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-AA-031	anti-MIgG(Fc)Fab-N-DM1 ADC	Noncleavable linkers	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-W-484	Anti-CD22 (clone hu10F4)-MCC-DM1 ADC	MCC (Maleimidomethyl cyclohexane-1-carboxylate)	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-W-572	Anti-ERBB2 (Trastuzumab-Fab)-SPP-DM1 ADC	SPP (N-succinimidyl-4-(2-pyridyldithio)pentanoate)	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-W-460	Anti-NCAM1 (clone huN901)-SPP-DM1 ADC	SPP (N-succinimidyl-4-(2-pyridyldithio)pentanoate)	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)

Online Inquiry

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.